FDANews
FDAnews Drug Daily Bulletin

Health Canada Approves Novo Nordisk’s Mealtime Insulin

April 3, 2017

Novo Nordisk Canada has received approval and marketing clearance from Health Canada for its Fiasp insulin.

Fiasp is an insulin analog that more closely matches the natural physiological insulin response of a person without diabetes following a meal, compared to NovoRapid, the company said.

Fiasp can also be taken up to two minutes before a meal and up to 20 minutes after starting a meal without compromising glycemic control or safety.

Fiasp received marketing authorization from the European Commission, and is currently under regulatory review in Switzerland, Australia, Brazil, South Africa and Argentina.

View today's stories